Stem Cell Clinic

"American Journal of Sports Medicine" publishes results of an FDA-approved clinical trial for treating osteoarthritis knee pain – Yahoo…

Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees

LOUISVILLE, Colo. andNEW ORLEANS andSAN ANTONIO andCHICAGO, March 2, 2020 /PRNewswire/ -- GID BIOannounced today that The American Journal of Sports Medicinepublished resultsof its FDA-approved multi-site, randomized, placebo-controlled Phase IIb clinical trial measuring the safety and efficacy of its SVF-2 device and point-of-care (POC) therapy intended to treat pain and function associated with knee osteoarthritis.

The Phase IIb clinical study was approved by the FDA under an IDE and is the first regenerative cell therapy for osteoarthritis to meet study endpoints using autologous stromal cells from adipose tissue. The cellular therapy for osteoarthritis procedure showed no serious adverse events at two years and a significant reduction in pain at one year. A Phase III pivotal study begins soon at Tulane University School of Medicinewith additional trial sites participating nationwide.

"Publishing this data signifies real science and a breakthrough in regenerative medicine. We've completed a prior safety trial, an FDA-approved Phase IIb trial, and are now beginning a Phase III pivotal trial. Physicians will be able to use the SVF-2 technology to provide a cellular therapy option for patients," said principal investigator for the Phase III trial, Jaime R. Garza, MD, DDS, FACS, Professor of Orthopedic Surgery and Center for Stem Cell Research and Regenerative Medicineat Tulane University School of Medicine. "I am very proud to collaborate with my alma mater, Tulane University, and the School of Medicine's outstanding orthopedic department led by Dr. Felix Savoie, and its worldclass Center for Stem Cell Research and Regenerative Medicine directed by expert cell scientist Dr. Bruce Bunnell," said Dr. Garza.

Dr. Garza is a former NFL player and a Tulane University Athletic Hall of Fame inductee. He is also a clinical professor of plastic surgery and otolaryngology at the University of Texas Health Science Center.

Treatments by clinics using stem cells are under scrutiny by the FDA as its discretionary enforcement period expires in November of this year. The intent is that hundreds of stem cell clinicsnationwide become compliant with FDA regulations, leading to clinical data support of safety and efficacy.

"Our randomized, controlled clinical trial is the first cellular therapy study for osteoarthritis to meet study endpoints using autologous adipose stromal cells for a point-of-care therapy.Eighty-eight percent of subjects responded greater than placebo at one year and reported a median 87% improvement in pain, stiffness and function," said William W. Cimino, Ph.D., CEO of GID BIO. "We are able to isolate and concentrate the right types and numbers of cells to create an effective therapy. We are pleased to begin Phase III trials with Dr. Garza, and to be at the forefront for a cellular therapy option for osteoarthritic knees."

About GID SVF-2 and POC TherapyGID technology has reduced a Good Manufacturing Practice (GMP) cell-processing facility to a single-use disposable device for scalable point-of-care cell processing. The technology uniquely harvests and isolates stromal cells from a patient's own adipose tissue that is then reimplanted by injection in a physician's office in less than two hours. Stromal cells play an essential role in the body's natural healing response, with a dynamic and reactive ability to participate in the healing process. The American Medical Associationgranted GID two new CPT class III codesthat became effective January 2020 as a step toward Medicare reimbursement.

Story continues

About GID BIOGID BIO develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ-specific diseases, with the goal of making cellular medicine available to as many people as possible. GID's SVF-2 device and POC therapy harnesses the innate healing power of a patient's own stromal cells. Information on GID's SVF-2 device, biologic cellular implants, POC therapy, osteoarthritis clinical program and GID's pipeline for treating degenerative disease in musculoskeletal conditions includes other indications including, dermal and organs, specifically, wound care and diabetes. Learn more: https://www.HealingIntelligently.com.

AboutTulane University School of MedicineOne of the nation's most recognized centers for medical education,Tulane University School of Medicineis a vibrant center for education, research and public service.Tulane School of Medicineis the second-oldest medical school in the Deep South and the 15th oldest medical school inthe United States.Tulane School of Medicinerecruits top faculty, researchers and students from around the world, and pushes the boundaries of medicine with groundbreaking medical research and surgical advances.Tulaneremains in the forefront of modern medical innovation and is equipping the next generation of medical professionals with the tools to succeed in the rapidly changing future of health care.

About American Journal of Sports MedicineAglobal organization with 3,000 members that generates evidence-based knowledge and promotes emerging research to educate orthopaedic surgeonsand a resource for the orthopaedic sports medicine community, American Journal of Sports Medicine is a peer-reviewed scientific journal, first published in 1972. It is the official publication ofAOSSMfeaturing 14 issues per year. The journal acts as an important forum for independent orthopaedic sports medicine research and education, allowing clinical practitioners the ability to make decisions based on sound scientific information.

Contact:Kellee Johnson, 312-751-3959 or kjohnson@ballastgroup.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/american-journal-of-sports-medicine-publishes-results-of-an-fda-approved-clinical-trial-for-treating-osteoarthritis-knee-pain-301014538.html

SOURCE GID BIO

Original post:
"American Journal of Sports Medicine" publishes results of an FDA-approved clinical trial for treating osteoarthritis knee pain - Yahoo...

Mucosal Barrier Injuries and Bloodstream Infections Associated With Hematologic Cancer Treatments Reduced With Nurse-Driven Protocol – Oncology Nurse…

The rate of mucosal barrier injury (MBI) laboratory-confirmed bloodstream infections (LCBIs) in patients who experience prolonged neutropeniaassociated with chemotherapy for hematologic cancers can be reduced throughnurse and physician education and implementation of an oral care bundle, accordingto a study published in JCO OncologyPractice.

The Centers for Disease Control and Prevention National HealthcareSafety Network (CDC-NHSN) established 2 criteria to differentiate LCBIs fromcentral line-associated bloodstream infections (CLABSIs), which were theidentification of an organism with a known relationship to the oral cavity or gastrointestinaltract and MBI-compatible signs or symptoms in patients with eithergraft-versus-host disease associated with allogeneic stem cell transplantationor neutropenia.

Mucosal barrier injury occurs during periods of prolonged neutropeniain patients receiving cytotoxic chemotherapy for hematologic malignancies. Theseevents can lead to life-threatening LCBIs caused by bacteria crossing compromisedintestinal and mucosal barriers. A multidisciplinary team at the University ofVirginia Health System (UVAHS) in Charlottesville sought to reduce the numberof MBI-LCBI events at their facility.

Using the CDC-NHSN criteria, retrospective reviews of 3 studies foundthat 71%, 44%, and 45% of CLABSI events met the criteria for MBI-LCBI. Therefore,the UVAHS team performed a single-institution retrospective analysis and found thatthe baseline number of events at the tertiary academic medical center was 1.1per month. The teams goal was to make a 25% reduction in the number of events permonth in patients undergoing inpatient chemotherapy for hematologicmalignancies by January 2019.

Root cause analysis revealed that interventions focused on mucositisprevention, assessment, and treatment could potentially reduce MBI-LCBI events.Rates of MBI-LCBIs were tracked for a baseline cohort and across implementationof 3 Plan-Do-Study-Act (PDSA) cycles.

The team identified 93 CLABSI events; the most common diagnoses wereacute myeloid leukemia (50%), acute lymphoblastic leukemia (18%), and multiplemyeloma (14%). Of the 93 CLABSI events, 53 (57%) met criteria for MBI-LCBI.Patients with MBI-LCBIs were an average of 55 years old and 20 (38%) werefemale. Sixteen organisms were identified as the cause of the infections, withthe most commonly identified organisms being Escherichia coli, Klebsiella pneumoniae, and Streptococcus mitis. The types of central lines associated withMBI-LCBI included internal jugular central lines (77), peripherally placedcentral lines (14), and subclavian placed lines (2).

Excerpt from:
Mucosal Barrier Injuries and Bloodstream Infections Associated With Hematologic Cancer Treatments Reduced With Nurse-Driven Protocol - Oncology Nurse...

Low back and neck pain is costing us a fortune. Here’s how to stop – KTVZ

If youre constantly seeking relief for bothersome back and neck pain, youre likely not alone, according to a study published Tuesday in JAMA.

In 2016, Americans and their insurance companies spent an estimated $134.5 billion on lower back and neck pain more than all forms of cancer combined.

Researchers estimated US public, private and out-of-pocket spending on health care for 154 health conditions from 1996 to 2016 and low back and neck pain was first, followed by other musculoskeletal conditions including joint and limb pain, then spending for diabetes, heart disease, falls and urinary diseases.

In terms of health and wellness, I think the study highlights [that] a lot of the issues could be prevented with proper wellness and nutrition balance in our lives, said Dr. Sheldon Yao, chair and professor of Osteopathic Manipulative Medicine at the New York Institute for Technologys College of Osteopathic Medicine. Yao was not part of the study.

Back pain can be debilitating, removing people from enjoying the activities of everyday life. This area of the body is composed of complex system of muscles, ligaments, tendons, disks and bones, which all coordinate to support the body.

Obesity, sedentary lifestyles, technology and poor diet have all been linked to back and neck pain.

Obesity is a giant epidemic that plays a part into back pain, Yao said, explaining that a loss of core strength due to obesity can put someone at increased risk for back pain.

Poor posture and a lack of core- and neck-strengthening exercises such as planks, neck-tilts, yoga and lifting weights also contribute to increased incidence of low back and neck pain, because weak muscles fail to properly support bones and are more prone to injury.

The amount of time a person spends sitting at their desk or bending over their cell phone can also be to blame.

Everyones on their smart phone now, constantly connected 24/7 and your posture is just looking forward, Yao said. The strain on a persons spine from constantly bending ones neck to text or browse can feel like the equivalent of 20 or 30 pounds, according to a 2018 study.

Processed foods such as gluten, trans fats and added sugar have been linked to creating inflammation in the body which can lead to chronic pain, according to Harvard Universitys Harvard Medical School. Thats because inflammation can cause muscles to weaken, swell or feel painful, according to the National Institute of Neurological Disorders and Stroke.

Those are things where, as a society, we are not balanced, Yao said. Im not saying you cant eat any of those things, but just be aware of how much were taking in in terms of those inflammatory foods.

Health care spending on neck and back pain has increased each year since 1996, the study found, including newer and more expensive treatments such as stem cell and plasma injections, and an increase in surgeries instead of outpatient treatment.

The dollars dont appear to be well-spent, said Dr. Joseph Dieleman of the Institute for Health Metrics and Evaluation at the University of Washingtons School of Medicine.

The big picture trend suggests that all of the spending isnt essentially leading to fewer cases, said Dieleman, lead author of the study.

In fact, we see that the health burden essentially hasnt changed at all over time, despite the huge increases in spending, he said. It suggests that we have increased our spending a huge amount but were not necessarily getting a lot more for it.

There are ways to mitigate back and neck pain at home before it becomes a larger problem.

It might seem counterintuitive, but staying moderately active by going for a walk can help reduce pain and prevent muscles from weakening.

One of the biggest misconceptions is, I hurt myself. I need to go on complete bed rest and lie in bed and do nothing, Yao said. Thats been shown to really not be effective and ideally they need to try to maintain some form of activity as much as they can, and thats been shown to have positive results.

Eating healthier can not only reduce the inflammation that can lead to chronic back pain; it can also help someone lose excess weight, another factor of back pain.

Chronic back pain can be emotionally straining in addition to the physical symptoms.

To manage frustration, depression and other psychological side effects, Johns Hopkins Medicine recommends mindfulness and meditation as two nonsurgical methods for easing back pain. Taking breaks from activity when needed and being patient with yourself can prevent the condition from advancing.

Lower back pain can stem from a range of causes, from a mild strain to a traffic accident. If pain becomes something more serious, its important to seek additional care from a doctor instead of self-medicating, Yao said. Doctors can recommend multiple treatments including muscle relaxants, injections and physical therapy.

Yao said the study highlights the extent to which society as a whole can improve on their muscle and joint health and ensure that patient care is at the forefront.

Exercise is the last thing we do, eating right is the last thing we do, Yao said. Society as a whole is so stressed and overworked and taxed out that health becomes really on the back burner.

Patients have to take care of and responsibility for their own health. The more that a doctor can help facilitate that, the better.

Continued here:
Low back and neck pain is costing us a fortune. Here's how to stop - KTVZ

Stem Cell Alopecia Treatment Market 2020 Analysis by Overview, Growth, Top Companies, Trends, Demand and Forecast to 2026 – Packaging News 24

Verified Market Research adds new research report on market size for Stem Cell Alopecia Treatment and regional forecasts for 2020-2026. The report provides an in-depth analysis of the Stem Cell Alopecia Treatment market, taking into account market dynamics, segmentation, geographic expansion, the competitive landscape, and various other key issues. The market analysts who prepared the report have thoroughly examined the Stem Cell Alopecia Treatment market and provided reliable and accurate data. They understand the needs of the industry and customers, so they can easily focus on the issues that end users have been looking for. The research report provides an analysis of an assessment of existing and upcoming trends in which players can invest. It also includes an assessment of the players financial prospects and the nature of the competition.

This report includes the following Companies; We can also add other companies you want:

Stem Cell Alopecia Treatment Market: Competitive Landscape

The competitive landscape is a must for market participants to withstand the competition in the Stem Cell Alopecia Treatment market. This helps market participants to develop effective strategies to optimize their market positions. In addition, the competitive analysis helps them identify potential benefits and obstacles in the Stem Cell Alopecia Treatment market. This allows them to monitor how their competitors are implementing different strategies, including pricing, marketing, and sales.

Stem Cell Alopecia Treatment Market: Drivers and Limitations

The report section explains the various drivers and controls that have shaped the global market. The detailed analysis of many market drivers enables readers to get a clear overview of the market, including the market environment, government policy, product innovation, development and market risks.

The research report also identifies the creative opportunities, challenges, and challenges of the Stem Cell Alopecia Treatment market. The framework of the information will help the reader identify and plan strategies for the potential. Our obstacles, challenges and market challenges also help readers understand how the company can prevent this.

Stem Cell Alopecia Treatment Market: Segment Analysis

The report section contains segmentations such as application, product type and end user. These segments help determine which parts of the market will improve over others. This section analysis provides information on the most important aspects of developing certain categories better than others. It helps readers understand strategies to make solid investments. The market for Stem Cell Alopecia Treatment is segmented according to product type, applications and end users.

Stem Cell Alopecia Treatment Market: Regional Analysis

This section of the report contains detailed information on the market in different regions. Each region offers a different market size because each state has different government policies and other factors. The regions included in the report are North America, Europe, Asia Pacific, the Middle East and Africa. Information about the different regions helps the reader to better understand the global market.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=PN24&utm_medium=002

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market , By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market , By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market , By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market , By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Report Customization @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=PN24&utm_medium=002

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Alopecia Treatment Market Size, Stem Cell Alopecia Treatment Market Growth, Stem Cell Alopecia Treatment Market Forecast, Stem Cell Alopecia Treatment Market Analysis, Stem Cell Alopecia Treatment Market Trends, Stem Cell Alopecia Treatment Market

Follow this link:
Stem Cell Alopecia Treatment Market 2020 Analysis by Overview, Growth, Top Companies, Trends, Demand and Forecast to 2026 - Packaging News 24

Stem Cell Therapy Market 2020 Analysis by Overview, Growth, Top Companies, Trends, Demand and Forecast to 2026 – Packaging News 24

Verified Market Research adds new research report on market size for Stem Cell Therapy and regional forecasts for 2020-2026. The report provides an in-depth analysis of the Stem Cell Therapy market, taking into account market dynamics, segmentation, geographic expansion, the competitive landscape, and various other key issues. The market analysts who prepared the report have thoroughly examined the Stem Cell Therapy market and provided reliable and accurate data. They understand the needs of the industry and customers, so they can easily focus on the issues that end users have been looking for. The research report provides an analysis of an assessment of existing and upcoming trends in which players can invest. It also includes an assessment of the players financial prospects and the nature of the competition.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

This report includes the following Companies; We can also add other companies you want:

Stem Cell Therapy Market: Competitive Landscape

The competitive landscape is a must for market participants to withstand the competition in the Stem Cell Therapy market. This helps market participants to develop effective strategies to optimize their market positions. In addition, the competitive analysis helps them identify potential benefits and obstacles in the Stem Cell Therapy market. This allows them to monitor how their competitors are implementing different strategies, including pricing, marketing, and sales.

Stem Cell Therapy Market: Drivers and Limitations

The report section explains the various drivers and controls that have shaped the global market. The detailed analysis of many market drivers enables readers to get a clear overview of the market, including the market environment, government policy, product innovation, development and market risks.

The research report also identifies the creative opportunities, challenges, and challenges of the Stem Cell Therapy market. The framework of the information will help the reader identify and plan strategies for the potential. Our obstacles, challenges and market challenges also help readers understand how the company can prevent this.

Stem Cell Therapy Market: Segment Analysis

The report section contains segmentations such as application, product type and end user. These segments help determine which parts of the market will improve over others. This section analysis provides information on the most important aspects of developing certain categories better than others. It helps readers understand strategies to make solid investments. The market for Stem Cell Therapy is segmented according to product type, applications and end users.

Stem Cell Therapy Market: Regional Analysis

This section of the report contains detailed information on the market in different regions. Each region offers a different market size because each state has different government policies and other factors. The regions included in the report are North America, Europe, Asia Pacific, the Middle East and Africa. Information about the different regions helps the reader to better understand the global market.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=PN24&utm_medium=001

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market , By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market , By Solution

6.1 Overview

7 Stem Cell Therapy Market , By Vertical

7.1 Overview

8 Stem Cell Therapy Market , By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Report Customization @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=PN24&utm_medium=001

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Therapy Market Size, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis, Stem Cell Therapy Market Trends, Stem Cell Therapy Market

Read more here:
Stem Cell Therapy Market 2020 Analysis by Overview, Growth, Top Companies, Trends, Demand and Forecast to 2026 - Packaging News 24

2020-2025 Global and Regional Stem Cell Therapy for Osteoarthritis Industry Production, Sales and Consumption Status and Prospects Professional Market…

The global Stem Cell Therapy for Osteoarthritis market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Stem Cell Therapy for Osteoarthritis market, offers profound understandings about the Stem Cell Therapy for Osteoarthritis market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Stem Cell Therapy for Osteoarthritis focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4361431

Manufacturer Detail

By Market Players:Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics

By Application

By TypeMonotherapy, Combination Therapy

The Stem Cell Therapy for Osteoarthritis market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Stem Cell Therapy for Osteoarthritis market. This report on Stem Cell Therapy for Osteoarthritis has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Stem Cell Therapy for Osteoarthritis research study by HNY Research offers collection of information and analysis for each facet of the Stem Cell Therapy for Osteoarthritis market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-stem-cell-therapy-for-osteoarthritis-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Stem Cell Therapy for Osteoarthritis report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4361431

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read the rest here:
2020-2025 Global and Regional Stem Cell Therapy for Osteoarthritis Industry Production, Sales and Consumption Status and Prospects Professional Market...

Young priest receives news of fatal disease, offers up suffering in reparation for sin – Lifesite

March 3, 2020 (LifeSiteNews) A U.S. Catholic priest is counting his blessings including the support of the communities he has shepherded the last five years following his recent diagnosis with a progressive neurodegenerative disease.

The way of the cross that Jesus is inviting me to walk will not be easy, but He and His holy Mother Mary will uphold me. I continue to do my best to surrender myself to Jesus knowing that He will take care of everything, the Rev. Dana Christensen posted on his personal Facebook page Dec. 21.

Christensen, 42, had been diagnosed with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrigs Disease, earlier that week.

ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord, according to the ALS Association website. The progressive degeneration of the motor neurons in ALS eventually leads to their demise. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, people may lose the ability to speak, eat, move and breathe.

While there is no cure for ALS, he is taking medications that may slow its progress, and he is engaged in clinical trials at the Mayo Clinic in Rochester, Minn.

I am personally at peace with this, although I have my moments, he wrote Dec. 21. I am convinced that this is a mysterious gift from God through the hands of Our Lady of Fatima to bring me to salvation and entrust me with the mission to live my priesthood in a new way.

Christensen, who has been otherwise healthy all his life, began to notice that things were not right in July. It started with muscle twitching and changes to his voice. Initially, he saw his primary care physician, who sent him to a neurologist, where a series of tests were conducted, with an attempt to rule out ALS and other serious diseases.

I really didnt realize how serious it was until I got the phone call the end of October telling me the working diagnosis was ALS, he said. Then things got real serious, real fast.

Christensen called the timing of that phone call providential, as he received it as he journeyed home from a pilgrimage to Fatima, Portugal, where Catholics believe that Mary appeared to three children, predicting the future of the world and calling upon Christians to pray the rosary daily and make sacrifices on behalf of sinners.

I see in (the timing of the call) the protection of Our Blessed Mother Mary, Christensen said.

But his acceptance of the diagnosis has not been without struggle.

After the first diagnosis, I went through what I call a period of freaking out, including a deep depression, panic attacks and fear, the priest shared. However, with time and lots of prayer, I have come to have peace about it. I know, beyond a shadow of a doubt, that God has allowed this for my own growth in holiness and is an opportunity to help others grow as well. I believe God will and is using this for good. I trust in Him.

In some ways, Christensen said the diagnosis has made him a better priest.

I thought I knew what to say and do for (those who have received bad news about their health), but once I was the one receiving that news, I realized how naive I had been. Until we get the bad news ourselves, we have no idea what it is like, he said.

Christensen said that his health has revealed a call from God to practice what I preach.

I often preach about being confident in Gods Mercy and trusting His plan for our lives, he said. Now I have to put it into practice.

On Jan. 10, the Catholic Feast of the Baptism of the Lord, Christensen told his congregation of a puzzling inscription over a doorway in Greece that says, If you die before you die, when you die, you will not die.

The priest explained that, in baptism, Christians are buried in water and rise up to live their lives differently.

With his voice wavering from the effects of his ALS, Christensen told parishioners, If, all of our life, we take up our cross and die daily to ourselves, if we choose Gods will instead of our own, if we accept all of the daily deaths that come to us, whether it be grief, whether it be illness, whether it be any number of daily dyings that come to us, if we live those as Jesus did, if we allow Him to die in us, then we have nothing to fear. For, when our death comes, we will have already died, and all that will be left for us is to live eternally.

Following delivery of that sermon, Christensen shared that a priest always preaches to himself first and foremost, and that it was a good summation of how I see this. It helps me to not fear death, because of having already died with Christ, what is there to fear?

Christensen continues to pastor the Catholic parishes in Alexandria, Emery and Bridgewaterbetween appointments with a variety of doctors at the Mayo Clinic in Rochester, Minn., where he will undergo experimental treatment for ALS.

In his initial Facebook post, Christensen asked followers to to pray for a miraculous healing through the intercession of Venerable Fulton J. Sheen using the following prayer:

Eternal Father, You alone grant us every blessing in Heaven and on earth, through the redemptive mission of Your Divine Son, Jesus Christ, and by the working of the Holy Spirit. If it be according to Your Will, glorify Your servant, Archbishop Fulton J. Sheen, by granting the favor I now request through his prayerful intercession (in a miraculous healing for Fr. Christensen). I make this prayer confidently through Jesus Christ, Our Lord. Amen.

I believe in miracles, and as (God) did for the leper who cried out to Him, Lord, if thou wilt, thou canst make me clean, (Luke 5:12), He can also heal me, Christensen continued.

Sheen was one of the greatest preachers in modern Catholicism in these United States, and was really the first to use television to preach the Gospel, Christensen explained recently.One of the ways the Church uses to decide if a person is worthy of sainthood is for unexplained miracles to happen through their intercession in heaven. So, often when a miracle is desired, we turn to those being considered for sainthood, asking them to pray for us in heaven.Since we know from Sacred Scripture that God is a God of the living, and that all in heaven are alive in Christ, and that the saints in heaven intercede for us on earth, we ask them to pray for us just as we ask those living on earth to pray for us.

Acknowledging that, typically, ALS is a death sentence, Christensen continued in his initial post that he has surrendered to what will become of him.

As in all things, not my will, but His be done, he wrote. I accept whatever He has in store for me, and I offer it to Jesus through the hands of Mary, in reparation for my own sins and the sins of the whole world, and for the salvation of sinners.

Recently, Christensen shared that he had given Jesus and his mother, Mary, permission to do whatever it takes to makeme a saint.

I believe that this is a mysterious answer to this prayer, he said. I believe that Jesus is allowing me to be united to Him in His suffering, so that I may be united with Him in His glory.

Admitting he is a proud man, Christensen also suggested that his ALS is an attempt by God to humble him, to become little and in need of help to teach me that He is everything. It is only in becoming weak that we are made strong in Jesus, he said.

Christensen attributed his outward strength and optimism in the wake of his daunting diagnosis to God and his grace working through others.

It is astounding to me that people fromliterally around the world are praying for me, he said.

Though his strength and grace in the face of medical uncertainty have been noted by parishioners and others in the area, Christensen also asked that the faithful pray for his continued surrender to what will be, as well as for the comfort of his family, who have been instrumental in his care thus far.

By our prayers you will accompany me on my own way of the cross, he said.

To help with whatever care Christensen may need, local parishioners are spearheading additional practical aid. A fund has been created to offset the expenses of experimental treatment that isnt covered by insurance at Security State Bank in Alexandria. Those wishing to contribute to the fund can make deposits to the Padre Christensen Fund at the bank.

The funds, according to a press release, will cover experimental drugs or ethical stem cell treatments, travel to and from appointments, lodging, skilled in-home nursing and other future expenses related to Christensens care. Those with questions regarding fundraising efforts are invited to contact Camille Davies (605-933-0574 or [emailprotected]) or Don Wenande (605-770-0595 or [emailprotected]). In addition to the bank fund, Padres Fight t-shirts and sweatshirts are for sale.

Editors note: This article first appeared in The Alexandria Herald and The Emery Enterprise. It is republished here by permission of the author.

The rest is here:
Young priest receives news of fatal disease, offers up suffering in reparation for sin - Lifesite

CytoDyn Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to…

VANCOUVER, Washington, March 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive data for its mTNBC and MBC patients.

Metastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has a poor prognosis. In addition, metastatic breast cancer (MBC) is breast cancer that has spread beyond the breast and lymph nodes to other organs in the body (typically the bones, liver, lungs, or brain). Both types of cancer pose significant challenges for patients due to their aggressiveness and limited treatment options. An integral part of CytoDyns mission and purpose is to provide effective therapeutic solutions to these patients. Results of the first five patients are as follows:

Patient #1: Enrolled in mTNBC Phase 1b/2 - Injected on 9/27/2019. CTC (circulating tumor cells) dropped to zero in two weeks on 10/11/2019. Total CTC and EMT (Epithelial Mesenchymal Transition in Tumor Metastasis) dropped to zero after about one month of treatment with leronlimab (once-a-week 350 mg dose). Results from the patients earlier CT scan indicated a more than 25% tumor shrinkage within the first few weeks of treatment with leronlimab. Most importantly, after more than five months of treatment with leronlimab and Carboplatin, the patient not only has zero CTC and zero EMT, but also zero detectible CAML (cancer-associated microphages like cells).

Patient #2: Enrolled in single IND. Patient is MBC with HER2+ stage 4 metastasis to lung, liver, and brain. Patients radiologist cancelled 2nd round of treatment due to leronlimabs effect on shrinking the largest tumor in the brain by 56% and other lesions being stable. Leronlimab has and continues to be the only treatment in place for brain metastasis after radiation was administered to this patient in July 2019. Four and one-half months after successful radiation treatment, the patient received her first dose of leronlimab (700 mg) and no other drugs to treat the brain metastasis. The 56% shrinkage in the brain lesions occurred after only two once-weekly injections of leronlimab. After 10 weeks of treatment with leronlimab, this patients CTC and EMT results were all zeros (results reported on 2/12/2020). The patients CT scan in mid-February was reported as stable.

Patient #3: Enrolled on 1/3/2020. This patients CAML counts decreased from 45 to 30. CTC+EMT are stable and there has been no change in the total number. Despite positive results, this patient stopped treatment due to complications with her implanted port, which was unrelated to leronlimab.

Patient #4: Enrolled on 1/7/2020. This patients total CTC dropped by 75% in the first two weeks of treatment with leronlimab. After almost five weeks of treatment, the CTC remained at zero.

Patient #5: Enrolled on 2/4/2020. This patient has traveled from England to receive leronlimab. Initial response from treatment indicated tumor shrinkage and, importantly, CTC dropped to zero after three weeks of leronlimab treatment.

Patients #6 and #7: Enrolled and waiting for the first results post-baseline results.

Patients #8 through #10: Will be injected in early March.

Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, Patients continue to be actively enrolled in this trial based on the expression of CCR5 on lymphocytes and macrophages in the tumor microenvironment. The proposed mechanism of action (MOA) consisting of inhibition of Tregs and repolarization of macrophages has demonstrated a predictable, sustained response that has reduced the size of primary and metastatic tumors and reduced circulating tumor cells in all patients tested so far.

Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, added, These findings are solidifying our belief of the four mechanism of actions (MOA) for leronlimab in the treatment of cancer, as previously verified through preclinical animal studies and in published papers. These MOAs indicate that leronlimab may potentially stop metastasis in many types of solid tumor cancers, trigger the bodys immune response system to destroy the cancer tumor and perhaps more. This could represent the beginning of the transformation of CytoDyn from a potential leader in HIV therapy to providing potentially a new innovative treatment opportunity to patients with various forms of cancer and potentially NASH, GvHD, MS, and perhaps many more indications. With the possibility of our first approval in HIV late this year, we could have over 30 label expansion opportunities post-HIV approval.

About Triple-Negative Breast CancerTriple-negative breast cancer (TNBC) is a type of breast cancer characterized by the absence of the three most common types of receptors in the cancer tumor known to fuel most breast cancer growthestrogen receptors (ER), progesterone receptors (PR) and the hormone epidermal growth factor receptor 2 (HER-2) gene. TNBC cancer occurs in about 10 to 20 percent of diagnosed breast cancers and can be more aggressive and more likely to spread and recur. Since the triple-negative tumor cells lack these receptors, common treatments for breast cancer such as hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.

About Leronlimab (PRO 140)The U.S. Food and Drug Administration (FDA) have granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is therefore conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additionalclinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Companys cash position, (ii)the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv)the Companys ability to enter into partnership or licensing arrangements with third parties, (v)the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Companys ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Companys clinical trials, (viii)the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTS

Investors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

Continue reading here:
CytoDyn Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to...